Prostaliss vs ProstaVitalis: Prostate Health and Heart Health Considerations

By UTCardiothoracicSurgery.com Editorial Team

Product Pages: ProstaLiss | ProstaVitalis

This article is for informational purposes only and should not be construed as medical advice. Please consult with both your cardiologist and urologist before starting any new supplement, especially if you are taking blood thinners, antiplatelet medications, or blood pressure medications. The FDA does not evaluate dietary supplements for safety or efficacy. These products are not intended to diagnose, treat, cure, or prevent any disease.

UTCTS Health Review Editorial Team | July 2026

Prostaliss vs ProstaVitalis: A Cardiac-Focused Review for Heart Patients with Prostate Concerns

For cardiac patients managing both heart health and prostate function, supplement selection becomes significantly more complex than for the general population. Every ingredient carries potential for drug-nutrient interactions with common cardiac medications—beta-blockers, ACE inhibitors, statins, anticoagulants, and antiplatelet agents. Prostaliss and ProstaVitalis are frequently marketed as interchangeable prostate support options, yet they differ in one critical ingredient that has direct cardiac safety implications: Cat's Claw, which ProstaVitalis includes and Prostaliss does not.

This review examines both formulas from a cardiovascular perspective, analyzing ingredient overlap, identifying interaction risks, and providing clear guidance on which product—if either—is appropriate for cardiac patients with benign prostatic hyperplasia (BPH) or prostate health concerns.

Dose-Matched Foundation: The Shared 9-Ingredient Base

Both Prostaliss and ProstaVitalis are built on the same disclosed core ingredient-and-dose pattern, containing these nine ingredients at identical doses:

• Saw palmetto berry extract: 320mg (standardized to 45% fatty acids)
• Nettle leaf extract: 300mg (3.3% standardized)
• Pygeum africanum bark extract: 100mg
• Green tea leaf extract (EGCG): 100mg
• Lycopene: 10mg
• Selenium: 140mcg (255% DV)
• Zinc: 15mg
• Pumpkin seed extract: 75mg
• Amino acid blend (arginine/citrulline): 200mg

This overlap means both formulas carry identical cardiac considerations regarding saw palmetto, green tea EGCG, selenium dosing, and the amino acid content. However, the critical divergence—ProstaVitalis's addition of Cat's Claw—introduces a separate set of cardiac safety concerns that warrants detailed examination.

The Cardiac Safety Issue: Saw Palmetto and Anticoagulation Risk

Saw palmetto is the cornerstone of both formulas. While research support for saw palmetto's efficacy in BPH has been questioned (notably by the CAMUS trial, PMID 21954478, which found saw palmetto no more effective than placebo in a large randomized trial), the ingredient remains widely used and is generally recognized as safe in recommended doses. For cardiac patients, however, the safety profile becomes more nuanced.

Multiple case reports and mechanistic studies suggest saw palmetto may enhance platelet aggregation inhibition and interact with antiplatelet medications (aspirin, clopidogrel) and anticoagulants (warfarin, direct oral anticoagulants). Cardiac patients frequently take both aspirin (for secondary prevention after MI or stroke) and anticoagulants (for atrial fibrillation, mechanical heart valves, or thromboembolism risk). The additive effect of saw palmetto plus antiplatelet/anticoagulant therapy could theoretically increase bleeding risk, though clinical bleeding events have been rare at standard doses. Still, the concern warrants caution and physician oversight.

Recommendation for cardiac patients: If on warfarin (Coumadin) or NOACs (apixaban, rivaroxaban, dabigatran), consult your cardiologist before starting either formula. If cleared by cardiology, request INR monitoring more frequently (baseline + 2-4 weeks post-initiation for warfarin patients) to detect any unexpected shifts.

Green Tea EGCG: Interaction with Heart Medications

Both formulas contain 100mg of green tea leaf extract standardized to EGCG. At this dose, clinically significant interactions are uncommon, but cardiac patients on specific medications should be aware of potential mechanisms.

Green tea EGCG research suggests it may to have mild blood pressure-lowering effects in some studies, and there is theoretical risk of additive hypotensive effects in patients on ACE inhibitors, ARBs (angiotensin receptor blockers), or beta-blockers. Additionally, EGCG may modestly reduce iron absorption—a concern for cardiac patients on iron supplementation (common in advanced heart failure or chronic kidney disease). Green tea can also mildly inhibit platelet aggregation, adding a small amount of additional anticoagulant/antiplatelet effect on top of saw palmetto.

At the 100mg dose in these formulas, the clinical risk remains low, but cumulative effects matter when a patient is taking multiple medications with similar mechanisms. Cardiac patients should inform their cardiologist that they are considering these products, providing a complete ingredient list for medical review.

ProstaVitalis Only: Cat's Claw and Anticoagulation Concerns

ProstaVitalis's distinguishing ingredients—the ingredient that sets it apart from Prostaliss—are Zinc 10mg (an additional 10mg boost beyond the 15mg in the base formula, for a total of 25mg; well within safe limits), a proprietary mushroom blend (lion's mane, cordyceps, reishi), and most critically, Cat's Claw 30mg.

Cat's Claw (Uncaria tomentosa), a woody vine from the Amazon, has a long traditional use in Peruvian medicine for inflammatory conditions. Modern research suggests it may support immune function and reduce inflammatory markers. However, emerging evidence also indicates Cat's Claw has anticoagulant and antiplatelet properties—mechanisms of action similar to those of blood thinners.

For the general population, Cat's Claw at 30mg is considered relatively safe. For cardiac patients on warfarin, aspirin, clopidogrel, or NOACs, the addition of Cat's Claw to an already-suspect-for-anticoagulant-interactions product (saw palmetto) creates a compound risk scenario. The combination of saw palmetto + green tea EGCG + Cat's Claw represents a cumulative anti-aggregation/anticoagulant-like effect that could materially increase bleeding risk in high-risk cardiac patients.

UTCTS Cardiac Safety Position: We recommend that cardiac patients on any anticoagulant or antiplatelet therapy avoid ProstaVitalis due to its Cat's Claw content. Prostaliss, while still requiring cardiology review, carries a lower interaction risk because it eliminates the Cat's Claw variable.

Selenium: High-Dose Concern for Multidrug Medication Regimens

Both formulas provide 140mcg of selenium, which represents 255% of the daily value. This dose exceeds the upper tolerable intake level (UL) of 400mcg/day only by a small margin when considering the total daily intake from diet plus supplement. However, in cardiac patients taking multiple medications, the concern is not acute toxicity but rather nutrient-drug interactions at the micronutrient level.

Selenium interacts with several cardiac medications. High-dose selenium can interfere with thyroid function, relevant because many cardiac patients also have hypothyroidism and take levothyroxine. Selenium may also modestly affect warfarin metabolism. At the 140mcg dose in these formulas, the clinical risk remains theoretical and low, but cardiac patients on complex medication regimens should be aware that every micronutrient addition increases the surface area for potential interactions.

Recommendation: Cardiac patients on levothyroxine or warfarin should inform their physicians of the selenium dose and request TSH and INR monitoring if both the supplement and medication are started or adjusted simultaneously.

Evidence for Efficacy: Modest and Mixed for Both Products

It is important to note that while both formulas contain established BPH-supporting ingredients, the clinical evidence for the combined formula's efficacy remains modest. The landmark CAMUS trial (PMID 21954478) tested saw palmetto 320mg twice daily (the exact dose in both Prostaliss and ProstaVitalis) against placebo in 225 men with BPH and found no statistically significant difference in symptom improvement over 72 weeks. Individual ingredients within the formulas show more promise: stinging nettle (PMID 16635963, showing ~50% symptom improvement in some studies), pygeum africanum (PMID 11099686, supporting urinary function and nocturia), and green tea EGCG (PMID 23235581, modest prostate antioxidant effects). However, the saw palmetto backbone of both formulas—while safe—remains controversial for efficacy.

Neither product should be viewed as a substitute for medical evaluation of lower urinary tract symptoms, which can indicate BPH, urinary tract infection, prostate cancer, or other conditions requiring urological assessment. Cardiac patients with BPH should be managed by both their cardiologist and urologist, with careful attention to any new medications or supplements.

Prostaliss vs ProstaVitalis: Who Should Use Which?

Prostaliss may be appropriate for: Cardiac patients with mild prostate concerns and no history of bleeding disorders or high bleeding risk. Patients on aspirin alone (low-dose prevention) or low-risk anticoagulants may tolerate Prostaliss with cardiology supervision. Patients with atrial fibrillation on rate-control medications (not anticoagulants) may also be candidates, provided blood pressure remains stable during use.

Prostaliss is not recommended for: Patients on warfarin, NOACs, or dual antiplatelet therapy (aspirin + clopidogrel); patients with recent bleeding events or bleeding disorders; patients on medications that interact with saw palmetto (consult your cardiologist for the specific list if you're unsure).

ProstaVitalis is not recommended for: Any cardiac patient on anticoagulants or antiplatelet therapy (due to Cat's Claw); patients with bleeding disorders; patients with high cardiovascular event risk. The added Cat's Claw moves ProstaVitalis into a higher-risk category for this population.

Both formulas are not recommended for: Cardiac patients who have not discussed supplement use with both their cardiologist and urologist. Patients with undiagnosed lower urinary tract symptoms (which require medical evaluation to rule out serious conditions). Patients on complex medication regimens involving multiple drug classes until each addition has been vetted by their care team.

Pricing and Commercial Terms

Both products are identically priced at $49.95 per month (60 capsules, 30-day supply at two capsules daily). Both offer a 60-day money-back guarantee, sold through the same major retailers, and manufactured by the same third-party facility. From a cost-benefit standpoint, neither product offers an economic advantage, making the cardiac safety profile the primary differentiator.

Internal Links and Related Cardiovascular Resources

Cardiac patients interested in prostate health may also benefit from exploring how BPH symptoms overlap with heart disease medication side effects, as several cardiac drugs (diuretics, beta-blockers) can affect urinary symptoms. Additionally, understanding drug interactions between supplements and heart medications is essential for safe supplement use in this population. For those concerned about anticoagulant interactions, review foods and supplements that interact with warfarin and NOACs for a comprehensive list. Finally, working with your cardiologist on supplement decisions can help you navigate the complex landscape of cardiac safety with nutraceuticals.

Who This is NOT For

Neither product is appropriate for:

• Patients on warfarin (Coumadin) or novel oral anticoagulants (NOACs) without explicit cardiologist approval
• Patients on dual antiplatelet therapy (aspirin + clopidogrel or other combinations)
• Patients with a history of gastrointestinal bleeding, intracranial hemorrhage, or other bleeding disorders
• Patients with hemophilia or other clotting disorders
• Patients on high-dose aspirin (>325mg daily) without medical supervision
• Patients with undiagnosed lower urinary tract symptoms (requires urological evaluation first)
• Patients who have not obtained explicit approval from both their cardiologist and urologist
• Patients allergic to any ingredient in either formula

The Bottom Line

Prostaliss and ProstaVitalis share a dose-matched 9-ingredient base but diverge in one critical area: ProstaVitalis's inclusion of Cat's Claw, which carries anticoagulant-like properties concerning for cardiac patients on blood thinners or antiplatelet agents. For the general population, both products are well-tolerated, though clinical evidence for BPH efficacy remains mixed and modest. For cardiac patients—particularly those on anticoagulants, antiplatelet therapy, or complex medication regimens—supplement selection must prioritize drug-nutrient interactions above all else. Prostaliss represents a lower-risk option than ProstaVitalis if either is used at all, but only after comprehensive discussion with both cardiology and urology. The safest approach remains conservative: cardiac patients with prostate concerns should address symptoms through medical evaluation and physician-guided management before considering supplementation. Any supplement addition should be preceded by a complete ingredient review with the treating cardiologist. Dosing, timing, and monitoring protocols should be established before initiation. This is particularly true for patients on high-risk medications such as warfarin or dual antiplatelet therapy. Cardiac safety is not negotiable, even when pursuing prostate health support. This article was last updated July 2026 and reflects evidence available at that date. Consult the most recent clinical literature and your healthcare providers for the latest guidance.

Frequently Asked Questions

Can I take Prostaliss or ProstaVitalis if I'm on aspirin for heart disease prevention?

Low-dose aspirin (81mg daily) for secondary prevention after MI or stroke may be compatible with Prostaliss if your cardiologist approves, but the combination requires monitoring. High-dose aspirin (>325mg daily) or dual antiplatelet therapy should prompt your cardiologist to advise against both products. Always ask your cardiologist for explicit approval before adding either supplement.

Is Cat's Claw in ProstaVitalis safe for someone not on blood thinners?

Yes, Cat's Claw at 30mg is generally well-tolerated in the general population. For non-cardiac patients or those without bleeding risk, ProstaVitalis's added ingredients (Cat's Claw, extra zinc, mushrooms) may provide marginal additional benefit, though clinical evidence is limited. If you have a history of bleeding, clotting disorders, or are on any anticoagulant or antiplatelet therapy, Cat's Claw becomes a concern.

Which product has stronger evidence for BPH symptom improvement?

Both formulas are built on the same disclosed core ingredient-and-dose pattern, so efficacy should be essentially equal if clinical benefit exists. The CAMUS trial found saw palmetto no more effective than placebo, raising questions about the entire ingredient class. Individual components (stinging nettle, pygeum) show modest promise in some studies, but the combined formula's effectiveness remains unproven in large trials.

Can I use either product while on levothyroxine?

Possibly, but with monitoring. Both formulas provide 255% of the daily selenium recommendation. Selenium can affect thyroid function and levothyroxine absorption if dosing is imbalanced. If you're on levothyroxine, request TSH monitoring 4-6 weeks after starting either supplement to ensure your thyroid remains stable. Some patients may need to adjust levothyroxine dosing slightly.

What should I do if I'm on warfarin and interested in prostate support?

Avoid both products without explicit cardiologist approval. If your cardiologist agrees to a trial, use only Prostaliss (not ProstaVitalis with Cat's Claw), start with a single capsule daily (rather than the recommended two), and increase INR monitoring frequency to baseline + weeks 2, 4, and 8 to detect any unexpected shifts. Work with your anticoagulation clinic (INR management team) and cardiologist in parallel. Discontinue immediately if INR rises significantly or if any bleeding signs appear.